疫苗联合研究和许可协议（2016-2024）

本报告审查了疫苗合作和许可协议，详细瞭解和分析了公司如何以及为何签订疫苗协议。

目录

执行摘要

第1章简介

第2章疫苗合约趋势

• 简介
• 过去几年的疫苗合约
• 最活跃的疫苗合约公司
• 疫苗合约：依合约类型
• 疫苗合约：依治疗领域划分
• 疫苗合约：依行业分类
• 疫苗合约条款与条件
  • 疫苗合约的总金额
  • 疫苗合约预付款
  • 疫苗合约里程碑付款
  • 疫苗特许权使用费率

第3章主要疫苗合约

• 简介
• 以价值排名最高的疫苗合约

第4章最活跃疫苗合约公司

• 简介
• 最活跃的疫苗合约公司
• 最活跃的疫苗承包商简介

第5章疫苗合约目录

• 简介
• 疫苗合约目录

第 6 章疫苗合约：依技术类型

• 合约目录
• 合约目录 - 疫苗合约：依公司分类（A-Z）
• 合约目录 - 疫苗合约：依合约类型
• 合约目录 - 疫苗合约：依治疗领域
• 合约类型的定义
• 关于生物製药研究股份有限公司
• 当前合作伙伴
• 当前协议
• Current Partnering 近期报告的标题

Vaccine Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the vaccine deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of vaccine deals from 2016 to 2024.

The report provides a detailed understanding and analysis of how and why companies enter vaccine deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 748 vaccine deals announced since 2016 including financial terms where available including links to online deal records of actual vaccine partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of vaccine dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in vaccine dealmaking since 2016.

Chapter 3 provides an overview of the leading vaccine deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in vaccine dealmaking with a brief summary followed by a comprehensive listing of vaccine deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of vaccine deals signed and announced since Jan 2016, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of vaccine partnering deals signed and announced since Jan 2016. The chapter is organized by specific vaccine technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in vaccine deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Vaccine Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse vaccine collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Vaccine Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of vaccine trends and structure of deals entered into by leading biopharma companies worldwide.

Vaccine Collaboration and Licensing Deals includes:

• Trends in vaccine dealmaking in the biopharma industry
• Directory of vaccine deal records covering pharmaceutical and biotechnology
• The leading vaccine deals by value
• Most active vaccine licensing dealmakers
• Vaccine Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in vaccine dealmaking

• 2.1. Introduction
• 2.2. Vaccine deals over the years
• 2.3. Most active vaccine dealmakers
• 2.4. Vaccine deals by deal type
• 2.5. Vaccine deals by therapy area
• 2.6. Vaccine deals by industry sector
• 2.7. Deal terms for vaccine deals
  • 2.7.1 Vaccine deals headline values
  • 2.7.2 Vaccine deal upfront payments
  • 2.7.3 Vaccine deal milestone payments
  • 2.7.4 Vaccine royalty rates

Chapter 3 - Leading vaccine deals

• 3.1. Introduction
• 3.2. Top vaccine deals by value

Chapter 4 - Most active vaccine dealmakers

• 4.1. Introduction
• 4.2. Most active vaccine dealmakers
• 4.3. Most active vaccine deals company profiles

Chapter 5 - Vaccine contracts dealmaking directory

• 5.1. Introduction
• 5.2. Vaccine contracts dealmaking directory

Chapter 6 - Vaccine dealmaking by technology type

• Deal directory
• Deal directory - Vaccine deals by company A-Z
• Deal directory - Vaccine deals by deal type
• Deal directory - Vaccine deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Vaccine deals since 2016
• Figure 2: Active vaccine dealmaking activity - 2016 - 2024
• Figure 3: Vaccine deals by deal type since 2016
• Figure 4: Vaccine deals by therapy area since 2016
• Figure 5: Vaccine deals by industry sector since 2016
• Figure 6: Vaccine deals with a headline value
• Figure 7: Vaccine deals with an upfront value
• Figure 8: Vaccine deals with a milestone value
• Figure 9: Vaccine deals with a royalty rate value
• Figure 10: Top vaccine deals by value since 2016
• Figure 11: Most active vaccine dealmakers 2016 - 2024
• Figure 12: Vaccine deals by technology type since 2016